drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (ADC)
drug_description
Investigational TROP-2–directed antibody–drug conjugate with a topoisomerase I payload.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
TROP‑2–targeted monoclonal antibody delivers a topoisomerase I inhibitor payload to TROP‑2–expressing tumor cells. After binding and internalization, linker cleavage releases the topo I inhibitor, causing DNA damage (single‑strand breaks) and tumor cell death, with potential bystander effect depending on linker permeability.
drug_name
ESG401
nct_id_drug_ref
NCT06145308